P3 Health Partners Inc expected to post a loss of 4 cents a share - Earnings Preview

P3 Health Partners

08/11/2024 22:01

* P3 Health Partners Inc  PIII.OQ   PIII.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * The Chicago Illinois-based  company is expected to report
a
26.4% increase in revenue to $364.449 million from $288.35
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for P3 Health Partners Inc
is for
a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for P3 Health
Partners Inc is $2.00​, above​ its last closing price of $0.37.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.07       -0.05      -0.09     Missed  -80
 Mar. 31 2024  -0.11       -0.11      -0.16     Missed  -50
 Dec. 31 2023  -0.19       -0.11      -0.22     Missed  -100​
 Sep. 30 2023  -0.29       -0.13      -0.12     Beat    45.5
 ​​Jun.        -0.14       -0.13      -0.09     Beat    30.8
 30 2023                                                
 Mar. 31 2023  -0.63       -0.67      -0.22     Beat    67.4​
 Dec. 31 2022              -0.91      -2.26     Missed  -148.4
 Sep. 30 2022  -0.47       -0.46      -0.27     Beat    41.7
 This summary was machine generated November 8 at 22:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)